Disease details

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01910259 (ClinicalTrials.gov)	December 18, 2014	19/7/2013	MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial	A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis.	Secondary Progressive Multiple Sclerosis	Drug: Amiloride;Drug: Riluzole;Drug: Fluoxetine;Drug: Placebo	University College, London	Medical Research Council;National Institute for Health Research, United Kingdom;MS Society;University of Edinburgh;Queen Mary University of London;Keele University;University of Sheffield;University of Leeds;University of Warwick	Completed	25 Years	65 Years	All	445	Phase 2	United Kingdom
2	EUCTR2012-005394-31-GB (EUCTR)	01/04/2014	05/09/2014	MS-SMART: A Trial of Efficacy (usefulness) of 3 Neuroprotective Drugs in SPMS	MS-SMART: A Multi-Arm Phase IIb Randomised, Double Blind Placebo-Controlled Clinical Trial Comparing The Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis - MS-SMART: Multiple Sclerosis Secondary Progressive Multi-Arm Randomisation Trial	Mutliple Sclerosis (Secondary Progressive);Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Rilutek Product Name: Rilutek INN or Proposed INN: Riluzole Trade Name: Amiloride Product Name: Amiloride INN or Proposed INN: Amiloride Trade Name: Fluoxetine Product Name: Fluoxetine INN or Proposed INN: Fluoxetine hydrochloride	UCL	NULL	Not Recruiting			Female: yes Male: yes	440	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom
3	NCT00501943 (ClinicalTrials.gov)	July 2006	12/7/2007	Neuroprotection With Riluzole Patients With Early Multiple Sclerosis	Neuroprotection With Riluzole in Patients With Early Multiple Sclerosis	Multiple Sclerosis	Drug: Avonex (Interferon beta 1a);Drug: Riluzole;Drug: Placebo	University of California, San Francisco	National Multiple Sclerosis Society;Oregon Health and Science University	Completed	18 Years	55 Years	All	43	Phase 2	United States
4	NCT00202397 (ClinicalTrials.gov)	June 2005	12/9/2005	Effect of Riluzole as a Symptomatic Approach in Patients With Chronic Cerebellar Ataxia	Phase 2 Study of Riluzole Effects on Patients With Chronic Cerebellar Ataxia	Hereditary Ataxia;Multiple Sclerosis;Cerebellar Ataxia	Drug: Riluzole;Other: placebo	S. Andrea Hospital	NULL	Completed	18 Years	80 Years	Both	40	Phase 2	Italy